<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019136</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064488</org_study_id>
    <secondary_id>NCI-96-C-0011</secondary_id>
    <secondary_id>NCI-T95-0040N</secondary_id>
    <nct_id>NCT00019136</nct_id>
    <nct_alias>NCT00001494</nct_alias>
  </id_info>
  <brief_title>Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer</brief_title>
  <official_title>TREATMENT OF PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER USING ANTI-CD3 STIMULATED PERIPHERAL BLOOD LYMPHOCYTES TRANSDUCED WITH A GENE ENCODING A CHIMERIC T-CELL RECEPTOR REACTIVE WITH FOLATE BINDING PROTEIN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill ovarian cancer&#xD;
      cells. Interleukin-2 combined with white blood cells that are gene-modified to recognize and&#xD;
      kill ovarian cancer cells may be an effective treatment for recurrent or residual ovarian&#xD;
      cancer.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of interleukin-2 plus gene-modified white&#xD;
      blood cells in treating patients who have advanced ovarian epithelial cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the clinical response in patients with advanced ovarian epithelial cancer&#xD;
           treated with intravenously administered allogeneic peripheral blood mononuclear&#xD;
           cell-stimulated, gene-modified lymphocytes (MOv-PBL).&#xD;
&#xD;
        -  Evaluate the ability of intravenously administered MOv-PBL to traffic to sites of&#xD;
           ovarian cancer.&#xD;
&#xD;
        -  Determine the duration of survival of transduced lymphocytes in the systemic circulation&#xD;
           and at the tumor site in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are stratified by eligibility to receive&#xD;
      interleukin-2 (IL-2) (yes vs no).&#xD;
&#xD;
      Patients undergo leukapheresis. The collected peripheral blood lymphocytes (PBLs) are&#xD;
      stimulated with allogeneic peripheral blood mononuclear cells (PBMCs) followed by retroviral&#xD;
      transduction with antiovarian cancer MOv-gamma chimeric receptor gene (MOv-PBL). MOv-PBL are&#xD;
      then reinfused IV over 30-60 minutes followed by IL-2 IV over 15-30 minutes every 12 hours&#xD;
      for up to 8 doses (if eligible). This course may be repeated at least once, beginning 2-3&#xD;
      weeks later. Patients receiving allogeneic PBMC-stimulated PBLs receive donor PBMCs&#xD;
      subcutaneously at 1 and 8 days after each MOv-PBL infusion instead of IL-2.&#xD;
&#xD;
      Cohorts of 3-6 patients in each stratum receive escalating doses of MOv-PBL until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity. An additional 10 patients receive MOv-PBL,&#xD;
      without IL-2, followed by immunization with donor PBMCs as above.&#xD;
&#xD;
      Patients are followed at 4 and 8 weeks and then periodically for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 13-50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1997</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MOv-gamma chimeric receptor gene</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven recurrent, resected recurrent, or residual ovarian epithelial&#xD;
             cancer&#xD;
&#xD;
          -  Failed prior standard effective therapy including cisplatin/carboplatin or paclitaxel&#xD;
&#xD;
          -  Tumor positive for folate-binding protein by monoclonal antibody MOv18 binding&#xD;
&#xD;
          -  Measurable disease by CT scan, MRI, ultrasound, or physical exam OR&#xD;
&#xD;
          -  Minimal residual disease on laparotomy, laparoscopy, or peritoneal washings (i.e.,&#xD;
             disease not evaluable radiologically or on physical exam)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0 or 1&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC greater than 3,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 9.0 g/dL&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Other liver function tests less than 3 times upper limit of normal&#xD;
&#xD;
          -  Hepatitis B antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No major cardiovascular illness&#xD;
&#xD;
          -  If history of ischemic heart disease, congestive heart failure, or cardiac&#xD;
             arrhythmias, not eligible to receive interleukin-2&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV_1 and DLCO greater than 70% predicted&#xD;
&#xD;
          -  No major respiratory illness&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  Must have an intact immune system as evidenced by a positive reaction to Candida&#xD;
             albicans, mumps, or tetanus toxoid skin tests on a standard anergy panel&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  More than 2 weeks since prior biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  More than 2 weeks since prior endocrine therapy&#xD;
&#xD;
          -  No concurrent steroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior debulking allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2003</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

